A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS FOR ORAL OZANIMOD (RPC1063) IN PEDIATRIC SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WITH AN INADEQUATE RESPONSE TO CONVENTIONAL THERAPY

Intervention/treatment:
OZANIMOD (RPC1063, BMS-986374)
Medical condition:
ULCERATIVE COLITIS
Protocol code:
IM047-001
Control number:
278329
Status:
Recruiting
Approved:
September 13, 2023
Trial phase:
Phase 2, Phase 3
For more information:
ClinicalTrials.gov - NCT05076175
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
2 Years to 17 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Role
CONTACT
Phone:
855-907-3286
Name
First line of the email MUST contain NCT # and Site #.
Role
CONTACT
Sponsor
BRISTOL-MYERS SQUIBB CANADA

Locations

Ontario

Local Institution - 0082
Toronto, Ontario, M5G 1X8
NOT_YET_RECRUITING
Name
Site 0082
Role
CONTACT
Local Institution - 0083
Hamilton, Ontario, L8N 3Z5
WITHDRAWN
Local Institution - 0104
Toronto, Ontario, M3M 0B2
NOT_YET_RECRUITING
Name
Site 0104
Role
CONTACT
Did you find what you were looking for?